- Home
- KALA vs NRSN Comparison
KALA vs NRSN Comparison
Compare KALA & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- NRSN
- Stock Information
- Founded
- KALA 2009
- NRSN 2017
- Country
- KALA United States
- NRSN Israel
- Employees
- KALA N/A
- NRSN N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- NRSN Health Care
- Exchange
- KALA Nasdaq
- NRSN Nasdaq
- Market Cap
- KALA 32.0M
- NRSN 26.3M
- IPO Year
- KALA 2017
- NRSN 2021
- Fundamental
- Price
- KALA $6.69
- NRSN $0.88
- Analyst Decision
- KALA Strong Buy
- NRSN
- Analyst Count
- KALA 2
- NRSN 0
- Target Price
- KALA $15.00
- NRSN N/A
- AVG Volume (30 Days)
- KALA 33.2K
- NRSN 206.0K
- Earning Date
- KALA 11-12-2024
- NRSN 12-03-2024
- Dividend Yield
- KALA N/A
- NRSN N/A
- EPS Growth
- KALA N/A
- NRSN N/A
- EPS
- KALA N/A
- NRSN N/A
- Revenue
- KALA N/A
- NRSN N/A
- Revenue This Year
- KALA N/A
- NRSN N/A
- Revenue Next Year
- KALA N/A
- NRSN N/A
- P/E Ratio
- KALA N/A
- NRSN N/A
- Revenue Growth
- KALA N/A
- NRSN N/A
- 52 Week Low
- KALA $4.21
- NRSN $0.51
- 52 Week High
- KALA $10.97
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- KALA 49.93
- NRSN 26.60
- Support Level
- KALA $6.00
- NRSN $0.91
- Resistance Level
- KALA $7.85
- NRSN $1.34
- Average True Range (ATR)
- KALA 0.40
- NRSN 0.07
- MACD
- KALA -0.11
- NRSN -0.05
- Stochastic Oscillator
- KALA 29.19
- NRSN 2.05
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.